Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jacobio Pharmaceuticals has announced that the U.S. FDA has approved their Investigational New Drug application for JAB-23E73, a drug aimed at treating cancer patients with KRAS mutations. The company plans to proceed with phase I/IIa clinical trials in the U.S. and awaits approval for trials in China. This announcement highlights Jacobio’s ongoing commitment to innovative cancer treatment solutions.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue